Last reviewed · How we verify
NCT03219307
Safety and Efficacy of NOVOCART 3D in the Treatment of Articular Cartilage Defects Following Failure on Microfracture
Phase 3 trial testing NOVOCART 3D in Articular Cartilage Defect in 30 participants. Participants enrolled and being followed up; not accepting new ones.
1 January 2026
Quick facts
| Lead sponsor | Aesculap Biologics, LLC |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 30 November 2018 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2029 |
| Sites | 5 locations across United States, Canada |
Drugs / interventions tested
- NOVOCART 3D — full drug profile →
Conditions studied
- Articular Cartilage Defect — all drugs for Articular Cartilage Defect →
Sponsor
Aesculap Biologics, LLC — full company profile →
Who can join
Adults 18 to 65, any sex, with Articular Cartilage Defect. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
KOOS pain subdomain score
Time frame: 24 months
Comparison of pain scores from the KOOS questionnaire from baseline
Sponsor's own description
This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Trends in clinical trials for articular cartilage repair by cell therapy.
Negoro T, Takagaki Y, Okura H, Matsuyama A. · · 2018 · cited 71× · PMID 30345076 · DOI 10.1038/s41536-018-0055-2 -
Cell therapy for cartilage repair.
Hulme CH, Perry J, McCarthy HS, Wright KT, et al · · 2021 · cited 35× · PMID 34423830 · DOI 10.1042/etls20210015 -
Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
Kim J, Park J, Song SY, Kim E. · · 2022 · cited 14× · PMID 35582708 · DOI 10.1016/j.reth.2022.04.004 -
Fabricating the cartilage: recent achievements.
Fani N, Peshkova M, Bikmulina P, Golroo R, et al · · 2023 · cited 3× · PMID 37389132 · DOI 10.1007/s10616-023-00582-2
Verify or expand the search:
- PubMed search for NCT03219307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Articular Cartilage Defect
Currently open trials in the same condition.
- NCT05402072 — AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03219307 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aesculap Biologics, LLC
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03219307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing